Psychedelics in Psychiatry: Early Medical Adoption and Practice-of-Medicine Gray Zones

Psychedelic therapy is increasingly becoming a part of clinical decision making, as evidenced by Compass Pathways’ announcement earlier this year of successful trial results for COMP360 psilocybin for treatment-resistant depression. Kimberly Chew, Senior Counsel, Husch Blackwell LLP, and L. Alison McInnes, MD, MS, Director of Psychedelic Medicine, Mindful Health Solutions, discuss the clinical realities and legal gray zones of psychedelic therapies as they move from controlled trials into rea...